Myriad Genetics faces ongoing legal and financial turbulence following a landmark Supreme Court ruling that invalidated its gene patents, ending its monopoly on BRCA genetic testing. The company posted a Q1 loss of $34.1 million as the decision reshapes the landscape of genetic testing access and patent law.
·Supreme Court ruled against Myriad's gene patents, determining that naturally occurring DNA sequences cannot be patented
·Association for Molecular Pathology v. Myriad Genetics case challenged whether companies can own genetic information
·Q1 financial results show $34.1 million loss, reflecting profitability concerns post-ruling
·Patent law precedent now prevents monopolies on naturally occurring genetic sequences
·Ruling opened genetic testing market to competitors, ending Myriad's exclusive control
drawn from simplywall.st, American Civil Liberties Union, Amazon Web Services (AWS), SCOTUSblog · updated 58d ago